^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MERTK inhibitor

    Related drugs:
    Apply
    A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies (NCT03522142)
    Phase 1
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    08/27/2018
    Primary completion :
    11/30/2024
    Completion :
    12/31/2024
    FLT3 • MSI • IDH1 • IDH2
    |
    MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type
    |
    Zynyz (retifanlimab-dlwr) • INCB81776
    Study of PF-07265807 in Participants With Metastatic Solid Tumors. (NCT04458259)
    Phase 1
    Pfizer
    Active, not recruiting
    Last update posted :
    04/03/2024
    Initiation :
    09/24/2020
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    PD-L1
    |
    PD-L1 expression
    |
    Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807
    Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative (NCT03758287)
    Phase 1/2
    Sunshine Lake Pharma Co., Ltd.
    Active, not recruiting
    Last update posted :
    06/22/2022
    Initiation :
    11/01/2016
    Primary completion :
    07/17/2023
    Completion :
    07/17/2023
    MET
    |
    EGFR mutation • EGFR T790M negative
    |
    gefitinib • ningetinib (CT053PTSA)
    A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (NCT04946890)
    Phase 1/2
    Betta Pharmaceuticals Co., Ltd.
    Not yet recruiting
    Last update posted :
    07/01/2021
    Initiation :
    07/01/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    FLT3
    |
    FLT3 mutation
    |
    MRX2843